|
1 Indications And Usage Inqovi Is Indicated For Treatment Of Adult Patients With Myelodysplastic Syndromes (Mds), Including Previously Treated And Untreated, De Novo And Secondary Mds With The Following French-American-British Subtypes (Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Anemia With Excess Blasts, And Chronic Myelomonocytic Leukemia [Cmml]) And Intermediate-1, Intermediate-2, And High-Risk International Prognostic Scoring System Groups. Inqovi Is A Combination Of Decitabine, A Nucleoside Metabolic Inhibitor, And Cedazuridine, A Cytidine Deaminase Inhibitor, Indicated For Treatment Of Adult Patients With Myelodysplastic Syndromes (Mds), Including Previously Treated And Untreated, De Novo And Secondary Mds With The Following French-American-British Subtypes (Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Anemia With Excess Blasts, And Chronic Myelomonocytic Leukemia [Cmml]) And Intermediate-1, Intermediate-2, And High-Risk International Prognostic Scoring System Groups. ( 1 )
|